Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells

Cellular and Molecular Immunology

Volumn 14, Issue 3, 2017, Pages 293-307

  Chen, Yan ^a   Chen, Bei ^a   Yang, Ti ^a   Xiao, Weiming ^a   Qian, Li ^a   Ding, Yanbing ^a   Ji, Mingchun ^a   Ge, Xiaoqun ^a   Gong, Weijuan ^a,b  

^a YANGZHOU UNIVERSITY   (China)

^b JC ICPCIAIDZ ^*  (China)

Author keywords

fusion protein; IL 15; NK cells; NKG2D; tumor

Indexed keywords

CD56 ANTIGEN; INTERLEUKIN 15; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; ANTINEOPLASTIC AGENT; HLA ANTIGEN CLASS 1; HYBRID PROTEIN; IL15 PROTEIN, HUMAN; IMMOBILIZED PROTEIN; KLRK1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; CELL MEMBRANE; DRUG SCREENING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMOBILIZED PROTEINS; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE, NUDE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85014676832     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.81     Document Type: Article

References (47)

1. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications incancer. Trends PharmacolSci2012; 33: 35-41
2. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 2011; 22: 99-108
3. Sanjabi S, Mosaheb MM, Flavell RA. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD81 T cells. Immunity 2009; 31: 131-144
4. Tao Q, Chen T, Tao L, Wang H, Pan Y, Xiong S, et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD31CD561 cells and downregulating regulatory T cells as well as IL-35. J Immunother 2013; 36: 462-467
5. Berger C, Berger M, Hackman RC, Gough M, Elliott C, JensenMCet al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114: 2417-2426
6. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 2014; 124: 1081-1088
7. Yiang GT, Chou RH, Chang WJ, Wei CW, Yu YL. Long-term expression of rAAV2-hIL15 enhances immunoglobulin production and lymphokine-activated killer cell-mediated human glioblastoma cell death. Mol Clin Oncol 2013; 1: 321-325
8. Zhao DX, Li ZJ, Zhang Y, Zhang XN, Zhao KC, Li YG, et al. Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas. Cell Immunol 2014; 289: 155-161
9. Bessard A, SoléV, Bouchaud G, Quéméner A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8: 2736-2745
10. Kermer V, Baum V, Hornig N, Kontermann RE, Müller D. An antibody fusion protein for cancer immunotherapy mimicking IL-15 transpresentation at the tumor site. Mol Cancer Ther 2012; 11: 1279-1288
11. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222: 357-368
12. Müller JR, Waldmann TA, Kruhlak MJ, Dubois S. Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15Ra in human monocytes and dendritic cells. J Biol Chem 2012; 287: 40328-40338
13. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26: 503-517
14. Castillo EF, Schluns KS. Regulating the immune system via IL-15 trans-presentation. Cytokine 2012; 59: 479-490
15. Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Mention JJ, et al. IL-15 trans-presentation promotes both human Tcell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci USA 2011; 108: 6217-6222
16. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005; 105: 721-727
17. Stoklasek TA, Schluns KS, Lefrançois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177: 6072-6080
18. Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD81/CD44high T cells and its antitumor action. J Immunol 2008; 180: 2099-2106
19. Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikb1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 2013; 121: 476-484
20. Bouchaud G, Garrigue-Antar L, SoléV, Quéméner A, Boublik Y, Mortier E, et al. The exon-3-encoded domain of IL-15R alpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol 2008; 382: 1-12
21. Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2013; 2: e26097
22. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-732
23. Hayakawa Y. Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets 2012; 16: 587-599
24. Salih HR, Holdenrieder S, Steinle A. Soluble NKG2D ligands: prevalence, release and functional impact. Front Biosci 2008; 13: 3448-3456
25. Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 2011; 71: 2066-2076
26. Xia Y, Chen B, Shao X, Xiao W, Qian L, Ding Y, et al. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice. J Immunother 2014; 37: 257-266
27. Gong W, Xiao W, Hu M, Weng X, Qian L, Pan X, et al. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand and interleukin-15. Tissue Antigens 2010; 76: 467-475
28. Lin Z, Wang C, Xia H, Liu W, Xiao W, Qian L, et al. CD4(1) NKG2D(1) T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1e transgenic mice. Immunology 2014; 141: 401-415
29. Mrózek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD561 natural killer cells from CD341 hematopoietic progenitor cells. Blood 1996; 87: 2632-2640
30. Barao I, Alvarez M, Redelman D, Weiss JM, Ortaldo JR, Wiltrout RH, et al. Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 2011; 17: 1754-1764
31. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 1999; 285: 727-729
32. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521-11526
33. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171
34. Zhang J, Xu Z, Zhou X, Zhang H, Yang N, Wu Y, et al. Loss of expression ofMHCclass I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma. Int J Clin Exp Pathol 2014; 7: 3123-3231
35. Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer 2013; 133: 1557-1566
36. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, et al. Disulphide-isomerase-enabled shedding of tumor-associated NKG2D ligands. Nature 2007; 447: 482-486
37. Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 2013; 78: 120-129
38. Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, et al. Normally occurring NKG2D1CD41 T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med 2009; 206: 793-805
39. Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006; 7: 755-762
40. Zhang C, Zhang J, Niu J, Zhang J, Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008; 42: 128-136
41. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113: 3503-3511
42. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111: 1428-1436
43. Bouchaud G, Gehrke S, Krieg C, Kolios A, Hafner J, Navarini AA, et al. Epidermal IL-15Ra acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. J Exp Med 2013; 210: 2105-2117
44. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008; 68: 8437-8445
45. González S, Groh V, Spies T. Immunobiology of humanNKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298: 121-138
46. Giri JG, Kumaki S Ahdieh M Friend DJ, Loomis A, Shanebeck K, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 1995; 14: 3654-3663
47. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413-441